<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507011</url>
  </required_header>
  <id_info>
    <org_study_id>1504M69361</org_study_id>
    <nct_id>NCT02507011</nct_id>
  </id_info>
  <brief_title>Beta-blockers in Pulmonary Arterial Hypertension</brief_title>
  <official_title>Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded,
      crossover trial of carvedilol in 26 PAH patients with World Health Organization functional
      class II or III symptoms and RV ejection fraction (EF) &lt; 45% for 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult PAH patients on a stable dose of an approved PAH medication will undergo the following
      baseline assessments: cardiac magnetic resonance imaging (MRI), right heart catheterization
      (RHC), echocardiogram, 6-minute walk test (6-MWT), plasma NT-ProBNP (biomarkers of RV
      function) and serum catecholamine (measure of sympathetic activation), and quality of life.
      Patients will be randomized to carvedilol (3.125 mg bid and escalated to 9.375 mg bid, as
      tolerated, over 3 months) or placebo in a 1:1 fashion. After 6 months, testing is repeated
      and patients are crossed over to the alternate treatment. Testing is repeated at the end of
      the study (month 13).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Right Ventricular Ejection Fraction as measured by cardiac MRI</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beta Blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>General Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Beta-adrenergic receptor blocker</description>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Beta-blockers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  WHO category 1 pulmonary arterial hypertension (Nice 2013)

          -  WHO functional class II-III

          -  RVEF by cardiac MRI &lt; 45%

          -  Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and
             functional class in the past 3 months. Patient can be on either mono or combination
             PAH-specific therapy

        Exclusion Criteria:

          -  Subjects will be excluded from participation in the study if any of the following
             conditions exist:

          -  Significant persistent bradycardia (resting heart rate &lt; 60 bpm) without a permanent
             pacemaker

          -  Second or third degree AV block without a permanent pacemaker

          -  Significant sinus tachycardia (resting heart rate &gt; 110 bpm)

          -  Use of anti-arrhythmic drugs

          -  Hypotension defined as systolic blood pressure &lt; 100 mmHg at the time of enrollment

          -  Significant illness in the past 30 days requiring hospitalization

          -  Acute decompensated right heart failure within past 30 days

          -  Known allergy or intolerance to carvedilol or other Î² blockers

          -  Cardiac index &lt; 2 l/min/m2 or right atrial pressure &gt; 15 mm Hg by right heart
             catheterization within last 3 months

          -  Asthma

          -  Positive pregnancy test in patients of child bearing-potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thenappan Thenappan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Beiches, RN</last_name>
      <phone>612-626-6237</phone>
    </contact>
    <investigator>
      <last_name>Thenappan Thenappan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

